Please assess the completion status of the following clinical trial:

Trial Title: Study of Remodulin® in Pediatric Pulmonary Hypertension With Single Ventricular Physiology After Fontan Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~After Fontan procedure, the criteria should be met~1. mPAP greater than 15 mmHg~2. TPG greater than 6 mmHg (exclude the obstruction of cavopulmonary anastomosis)~Exclusion Criteria:~After Fontan surgery :~1. Severe arrhythmia led to low cardiac output~2. Platelets smaller than 50,000\*109/L and obvious bleeding

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Remodulin Injection (Type: EXPERIMENTAL): Drug: Remodulin Injection Dosage:5 ng/kg/min-80ng/kg/min(0.15ml/hr-2.4ml/hr) Frequency: intravenous maintenance increase at a rate of 10ng/kg/min (0.3ml/hr)every 30 minutes Durations:48 hours
- Distilled water group (Type: PLACEBO_COMPARATOR): Drug:distilled water Dosage:0.15ml/hr-2.4ml/hr Frequency:increase at a rate of 0.3ml/hr every 30 minutes Durations:48 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).